AMYLYX PHARMACEUTICALS INC (AMLX) Stock Price, Quote, News and Overview
NASDAQ:AMLX - Nasdaq - US03237H1014 - Common Stock - Currency: USD
AMLX Quote, Performance and Key Statistics
8.18
+0.22 (+2.76%)
The current stock price of AMLX is 8.18 USD. In the past month the price increased by 17.19%. In the past year, price increased by 330.53%.
AMLX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 55.66 | 725.92B | ||
| JNJ | JOHNSON & JOHNSON | 17.07 | 411.20B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 16.77 | 230.92B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.3 | 227.91B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 12.97 | 209.82B | ||
| MRK | MERCK & CO. INC. | 10.49 | 202.87B | ||
| PFE | PFIZER INC | 7.71 | 140.71B | ||
| SNY | SANOFI-ADR | 10.9 | 116.68B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.81 | 93.31B | ||
| GSK | GSK PLC-SPON ADR | 8.33 | 75.30B | ||
| ZTS | ZOETIS INC | 24.27 | 65.05B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 47.33 | 44.85B |
Related stock screener links
About AMLX
Company Profile
Amylyx Pharmaceuticals, Inc. is a commercial-stage biotechnology company, which engages in the provision of therapies for neurodegenerative diseases and amyotrophic lateral sclerosis (ALS). The company is headquartered in Cambridge, Massachusetts and currently employs 123 full-time employees. The company went IPO on 2022-01-07. The firm is focused on three investigational therapies across several neurodegenerative and endocrine diseases. Its lead investigational asset is avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist. Avexitide has been evaluated as a treatment for Post-Bariatric Hypoglycemia (PBH) and congenital HI, two indications characterized by hyperinsulinemic hypoglycemia. In addition to avexitide, it is advancing AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol in Wolfram syndrome and progressive supranuclear palsy (PSP), and AMX0114 in amyotrophic lateral sclerosis (ALS). AMX0035 is designed to mitigate neurodegeneration by targeting endoplasmic reticulum stress and mitochondrial dysfunction, two cellular processes central to neuronal cell death and neurodegeneration. AMX0114 is an investigational antisense oligonucleotide.
Company Info
AMYLYX PHARMACEUTICALS INC
43 Thorndike Street
Cambridge MASSACHUSETTS US
Employees: 123
Phone: 16176820917
AMYLYX PHARMACEUTICALS INC / AMLX FAQ
What is the stock price of AMYLYX PHARMACEUTICALS INC today?
The current stock price of AMLX is 8.18 USD. The price increased by 2.76% in the last trading session.
What is the ticker symbol for AMYLYX PHARMACEUTICALS INC stock?
The exchange symbol of AMYLYX PHARMACEUTICALS INC is AMLX and it is listed on the Nasdaq exchange.
On which exchange is AMLX stock listed?
AMLX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for AMYLYX PHARMACEUTICALS INC stock?
15 analysts have analysed AMLX and the average price target is 11.86 USD. This implies a price increase of 44.96% is expected in the next year compared to the current price of 8.18. Check the AMYLYX PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is AMYLYX PHARMACEUTICALS INC worth?
AMYLYX PHARMACEUTICALS INC (AMLX) has a market capitalization of 729.17M USD. This makes AMLX a Small Cap stock.
How many employees does AMYLYX PHARMACEUTICALS INC have?
AMYLYX PHARMACEUTICALS INC (AMLX) currently has 123 employees.
What are the support and resistance levels for AMYLYX PHARMACEUTICALS INC (AMLX) stock?
AMYLYX PHARMACEUTICALS INC (AMLX) has a support level at 7.71 and a resistance level at 8.35. Check the full technical report for a detailed analysis of AMLX support and resistance levels.
Is AMYLYX PHARMACEUTICALS INC (AMLX) expected to grow?
The Revenue of AMYLYX PHARMACEUTICALS INC (AMLX) is expected to decline by -100% in the next year. Check the estimates tab for more information on the AMLX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy AMYLYX PHARMACEUTICALS INC (AMLX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of AMLX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of AMLX, evaluating the profitability, health, valuation and growth aspects
- AMYLYX PHARMACEUTICALS INC (AMLX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- AMYLYX PHARMACEUTICALS INC (AMLX) Sales and EPS estimates to see what analysts future expectations are.
- AMYLYX PHARMACEUTICALS INC (AMLX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- AMYLYX PHARMACEUTICALS INC (AMLX) Insider and Institutional Ownership to learn about the owners and their transactions.
- AMYLYX PHARMACEUTICALS INC (AMLX) Stock Chart to make your own analysis
- AMYLYX PHARMACEUTICALS INC (AMLX) Latest news and press-releases to stay up to date.
Does AMYLYX PHARMACEUTICALS INC (AMLX) stock pay dividends?
AMLX does not pay a dividend.
When does AMYLYX PHARMACEUTICALS INC (AMLX) report earnings?
AMYLYX PHARMACEUTICALS INC (AMLX) will report earnings on 2025-08-07, before the market open.
What is the Price/Earnings (PE) ratio of AMYLYX PHARMACEUTICALS INC (AMLX)?
AMYLYX PHARMACEUTICALS INC (AMLX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.77).
What is the Short Interest ratio of AMYLYX PHARMACEUTICALS INC (AMLX) stock?
The outstanding short interest for AMYLYX PHARMACEUTICALS INC (AMLX) is 10.31% of its float. Check the ownership tab for more information on the AMLX short interest.
AMLX Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to AMLX. When comparing the yearly performance of all stocks, AMLX is one of the better performing stocks in the market, outperforming 98.69% of all stocks.
AMLX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to AMLX. No worries on liquidiy or solvency for AMLX as it has an excellent financial health rating, but there are worries on the profitability.
AMLX Financial Highlights
Over the last trailing twelve months AMLX reported a non-GAAP Earnings per Share(EPS) of -2.77. The EPS decreased by -594.64% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -99.63% | ||
| ROE | -108.66% | ||
| Debt/Equity | 0 |
AMLX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 87% to AMLX. The Buy consensus is the average rating of analysts ratings from 15 analysts.
For the next year, analysts expect an EPS growth of 24.28% and a revenue growth -100% for AMLX